Biopharmaceutical venture capital fundraising is on the rise in 2024, boosted in part by surging numbers of $100m-plus mega-rounds, including a pair of large financings that ended June and started July – Formation Bio’s $372m series D round and a $170m series B for Beacon Therapeutics Holdings Limited.
Finance Watch: Q2 Ends, Q3 Begins With Latest Group Of VC Mega-Rounds
Two New Venture Funds Also Revealed
Private Company Edition: June ended with Formation Bio’s $372m series D round and July began with Beacon’s $170m series B. Also, Curie.Bio raised a $380m fund, Freeflow Ventures emerged with $90m across multiple funds and EvolutionaryScale raised a $142m seed round.
